Characteristics of COVID-19 cases and factors associated with disease severity in Lao People’s Democratic Republic: a nationwide study Authors: Souphatsone Houatthongkham, Phonepadith Xangsayarath, Bouaphanh Khamphaphongphane, Souphalak Inthaphatha, Ai Aoki, Kimihiro Nishino, Eiko Yamamoto Published: 2026 ABSTRACT ObjectivesThis is the first nationwide analysis to describe the epidemiological and clinical characteristics of COVID-19 cases in Lao People’s Democratic Republic (Lao PDR) and to identify factors associated with symptom-based disease severity during the early phase of the COVID-19 pandemic in Lao PDR.MethodsThis retrospective observational study analyzed 114,434 laboratory-confirmed COVID-19 cases reported in the national online surveillance system of the National Center for Laboratory and Epidemiology, Lao PDR, from 2020 to 2021.ResultsDuring 2020–2021, 1,408,839 suspected cases had tests for COVID-19 and 114,434 cases were confirmed positive. The cumulative number of laboratory-confirmed cases over the two-year period was 1,546.3 per 100,000 population and the case fatality rate was 0.14% (162 deaths). Most cases identified during the study period were aged 20–39 years, Laotian, residents in the central region, asymptomatic, and had received COVID-19 vaccinations. The factors associated with severe cases (n = 1,235, 1.08%) were males (adjusted odds ratio [AOR] = 1.43), older age (30–39 years, AOR = 1.44; 50–59 years, AOR = 1.74; 60–69 years, AOR = 2.01; and ≥ 70 years, AOR = 4.10) (vs. 0–9 years), Laotian (vs. foreigner; AOR = 4.42), employees of a non-governmental organization (AOR = 1.30) and prisoners (AOR = 1.76) (vs. unemployed), residents in the northern region (vs. the central region; AOR = 1.78), and the presence of comorbidity (AOR = 4.43). People living in the southern region (AOR = 0.67) and teachers (AOR = 0.40) were less likely to develop severe disease. Exposure in high-risk settings was associated with severity (AOR = 1.29), whereas travel-related (AOR = 0.48) and unlinked infections (AOR = 0.39) were inversely associated. Vaccination dose was not significantly associated with severe COVID-19 among all confirmed cases.ConclusionsSevere COVID-19 was rare in Lao PDR during 2020–2021 but occurred more frequently among males, older adults, cases with comorbidities, and residents of the northern region. No significant association was observed between vaccination dose and severe disease. Maintaining a robust surveillance infrastructure alongside evidence-based vaccination programs may strengthen preparedness for future public health emergencies in Lao PDR. Background Lao People’s Democratic Republic (Lao PDR) is a lower middle-income country that shares borders with Cambodia, China, Myanmar, Thailand, and Vietnam. Access to healthcare services is limited to most people because of insufficient resources [1]. When the coronavirus disease 2019 (COVID-19) pandemic began, it was expected that a major outbreak of COVID-19 would have a severe impact on the fragile healthcare system in Lao PDR. Surprisingly, Lao PDR was the final country in Southeast Asia to document a confirmed case of COVID-19 and the first death was reported on May 9, 2021 [2]. The number of confirmed cases in Lao PDR was much lower compared to low- and middle-income countries (LMICs) in Southeast Asia [3]. A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence survey further indicated that viral circulation in Lao PDR was limited before September 2020 [4]. In response to the World Health Organization’s statement regarding emerging the coronavirus and a cluster of pneumonia cases in China [5], the Ministry of Health of Lao PDR started COVID-19 testing and established a registration system for confirmed cases in January 2020 [6]. The National Task Force Committee for COVID-19 Prevention and Control was established on February 3, 2020, to make strategies and coordinate the country’s response efforts. Due to the confirmation of the first COVID-19 case on March 24, 2020, a nationwide lockdown was implemented from March 30 to May 3, 2020 [4]. The lockdown was effective in preventing the outbreak of COVID-19 and preparing the healthcare system for outbreaks. The second wave of COVID-19 was from April to December 2021. A partial lockdown was implemented on April 22, 2021; however, the number of confirmed cases increased significantly, coinciding with the emergence of the Alpha and Delta variants. Globally, COVID-19 incidence and case fatality rates (CFRs) varied widely during 2020 and 2021 [7]. Previous studies have reported associations between national income level and COVID-19 incidence and CFR, potentially reflecting differences in testing capacity, healthcare resources, demographic structure, and government effectiveness [8, 9]. Surveillance data indicate that COVID-19 incidence and CFR in Lao PDR were relatively low compared with other Southeast Asian countries during this period [3, 10]. This pattern is consistent with serological evidence suggesting limited SARS-CoV-2 transmission before late 2020 [4, 11]. These outcomes have been attributed to early public health interventions, strong community cooperation, and collaboration with international organizations, including non-governmental organizations (NGOs), United Nations agencies, and development partners, which supported surveillance, laboratory testing, clinical protocols, infection prevention, risk communication, personal protective equipment (PPE) procurement, and vaccine delivery [12, 13]. Previous studies have identified several factors associated with increased risk of severe COVID-19 and higher incidence, including older age, male sex, the presence of comorbidities such as cardiovascular disease, diabetes, and hypertension, high population density, occupational exposure, and limited access to healthcare services [14–17]. Close-contact settings, such as healthcare facilities and congregate living environments, have also been reported to increase the risk of infection and disease progression [18, 19]. In addition, vaccination has been consistently shown to reduce the risk of severe disease and death from COVID-19 [20, 21]. In Lao PDR, several of these factors appeared to be less prominent during the early phase of the pandemic. The population structure is relatively young, population density is low compared with many neighboring countries, and early public health measures limited large-scale outbreaks in high-risk settings. However, the extent to which these factors influenced disease severity at the individual level has not been well characterized. Therefore, this study aims to describe the epidemiological and clinical characteristics of COVID-19 cases in Lao PDR from 2020 to 2021 and to identify demographic and clinical factors associated with severe COVID-19. Methods Study design, study population, and case definition This retrospective observational study used data from the national COVID-19 registration system in Lao PDR. In accordance with the national surveillance guidelines of Lao PDR [22], a confirmed COVID-19 case was defined as a person who was positive for SARS-CoV-2 by real-time reverse transcription-polymerase chain reaction (RT-PCR), GeneXpert (Cepheid, Sunnyvale, CA, United States), or rapid diagnostic tests. The anonymized data were provided by the National Center of Laboratory and Epidemiology. All laboratory-confirmed cases registered during the study period were included, while suspected cases without laboratory confirmation were excluded. Data collection Suspected cases were identified through multiple surveillance pathways, including presentation to public health facilities, contact tracing, quarantine facilities, and border screening, in accordance with the national surveillance guidelines [22]. A suspected case was defined as a person who had a fever (≥ 38.0℃) or a history of fever within two weeks, had respiratory symptoms, had lost their sense of smell or taste, had close contact with a confirmed COVID-19 case within 14 days, or traveled to countries where a confirmed case was reported within 14 days. Close contact was defined as face-to-face contact with a confirmed case within 1 m and for more than 15 min, or physical contact with a confirmed case between two days before and 14 days after the onset of the disease of the confirmed case [22]. Samples from all suspected cases were collected using nasopharyngeal and throat swabs, while epidemiological data were gathered and registered online by trained epidemiology staff from both municipal and provincial epidemiology units. The data included the name, age, sex, nationality, occupation, address, health facility visited, date of onset, date of admission, and mobile phone number. When a suspected case tested positive for SARS-CoV-2, trained epidemiology staff contacted the person to inform them of the result, coordinated a doctor’s consultation or hospitalization, and collected additional information, such as comorbidities, symptoms, source of infection, vaccination status (doses and name of vaccine). Clinical symptoms were collected through standardized follow-up interviews conducted by trained public health staff as part of the national surveillance system, rather than through direct clinical examination by physicians. The staff called those who tested positive later to ask about the dates of admission and discharge if they were hospitalized. When cases were younger than 18 years old, the staff called their parents and collected information about the cases. When a confirmed case died, the health facility where the case died reported the death and date of the death to municipal and provincial epidemiology units. All data on suspected and confirmed cases, regardless of the surveillance pathway through which they were identified, were recorded in the centralized national COVID-19 online registration system, which was managed by the National Center for Laboratory and Epidemiology, the Ministry of Health. Key variables included in this study were mandatory fields in the system, and no missing data were observed for these variables in the analytical dataset. Socio-demographic factors The data in this study included socio-demographic factors (sex, age, nationality, occupation, and province of residence) and clinical data (date of registration, comorbidities, symptoms, source of infection, vaccination status, hospitalization, dates of admission and discharge, severity of COVID-19, and outcome). Age was categorized into eight groups (0–9 years, 10–19 years, 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70 years or older). The nationalities were divided into six categories, including Laotian, Asian (other than Laotian), European, North/South American, African, and Australian and Pacific Islander. Occupation categories were classified into 12 groups: unemployed, NGO employees, government employees, factory workers, security workers, healthcare workers, teachers, returnee workers (factory workers abroad who returned to Laos due to the pandemic), monks, prisoners, students, and dependents. Provinces of residence were categorized into three regions: central region (Vientiane Capital, Vientiane, Xaysomboun, Bolikhamxay, Khammuan, and Savannakhet Provinces), northern region (Phongsaly, Oudomxay, Luangnamtha, Bokeo, Xaiyabuly, Huaphan, Xiengkhuang, and Luangprabang Provinces), and southern region (Attapeau, Champasack, Sekong and Saravan Provinces). Clinical data Date of registration was categorized into 2020 and 2021. Comorbidities were recorded based on self-reported information obtained during case registration in the national surveillance system. Participants were asked whether they had any underlying diseases, such as cardiovascular diseases, lung diseases, tuberculosis, diabetes, or other chronic conditions. These conditions were not independently verified using medical records or standardized diagnostic criteria. There were four categories for the source of infection, such as close contact, exposure to high-risk settings, travel-related, and unlinked. Exposure to high-risk settings referred to situations in which people in healthcare facilities or laboratories handled body fluids, patient specimens, or performed aerosol-generating procedures without appropriate PPE, as well as instances where people in close-contact environments, such as prisons or factories, had face-to-face interactions with confirmed COVID-19 cases. ‘Travel-related’ referred to COVID-19 infection acquired during or shortly after international travel. ‘Unlinked’ referred to cases where the source of infection could not be identified through routine contact tracking. Vaccination status referred to doses of vaccination against COVID-19 received prior to laboratory confirmation of SARS-CoV-2 infection and was categorized into 0 dose, 1 dose, 2 doses, and 3 doses or more. This vaccination history included all doses received before infection, regardless of whether they were part of the primary vaccination series or booster doses. Vaccinations were categorized into three types, namely messenger RNA (mRNA) vaccine (BNT162b2, Pfizer–BioNTech), viral vector vaccine (ChAdOx1 nCoV-19, AstraZeneca PLC; Ad26.COV2.S, Johnson & Johnson/Janssen; Gam-COVID-Vac, Gamaleya Research Institute), and inactivated virus vaccine (BBIBP-CorV, Sinopharm; CoronaVac, Sinovac Biotech) [23]. Disease severity was classified according to the national COVID-19 surveillance criteria used in Lao PDR during the study period, as defined in the guideline “Case definition of COVID-19 for surveillance, reporting, and case classification of COVID-19” issued by the National Center for Laboratory and Epidemiology [24]. Cases were categorized as asymptomatic (no reported symptoms), mild (fever, cough, sore throat, runny nose, or loss of smell or taste), and severe (presence of dyspnea in combination with at least one other symptom) [24]. This classification was based on symptom reporting and surveillance definitions and does not necessarily correspond to internationally standardized clinical severity criteria, such as oxygen requirement or intensive care admission, although it is broadly consistent with public health-oriented severity stratification frameworks, including those of the World Health Organization. The length of hospitalization was calculated using the date of admission and discharge. Outcome was the status of the confirmed cases at discharge from health facilities, including alive and dead. Clinical information, including symptom status and comorbidities, was collected at the time of case confirmation through routine public health surveillance. Owing to limited healthcare workforce capacity during the pandemic, systematic clinical follow-up of all confirmed cases was not feasible. Therefore, disease severity was assessed based on symptoms reported at the time of registration rather than longitudinal clinical evaluation. COVID-19 laboratory testing Nasopharyngeal and throat swab specimens were collected from suspected cases and stored in Virus Transport Medium at 2–8 °C for up to 24 h before being transported to four national reference laboratories in Vientiane Capital. Specimens were examined for SARS-CoV-2 by real-time RT-PCR, GeneXpert, or rapid diagnostic tests. Data analysis Cumulative confirmed case rate per 100,000 population in 2020 and 2021 was calculated by dividing the total number of confirmed cases by the total population and multiplying by 100,000. This measure reflects the detection rate within the national surveillance system and should not be interpreted as a true epidemiological incidence rate, given the inclusion of asymptomatic cases and the potential for under-ascertainment. The total population was 7,346,533 in 2020 and 7,453,195 in 2021 [25]. The CFR was calculated by dividing the number of COVID-19 deaths by the number of confirmed cases and then multiplying by 100. Descriptive statistics were used to describe epidemiological data. Logistic regression analysis was performed to obtain the odds ratio (OR) and 95% confidence interval (CI). The binary classification (severe and non-severe outcomes) was used as the dependent variable in the logistic regression models and non-severe cases included asymptomatic and mild cases. Variables included in the multivariable model (sex, age, nationality, occupation, region, source of infection, comorbidity, and vaccination dose) were selected a priori based on clinical relevance and findings from previous studies. All selected variables were entered simultaneously into the model to adjust for potential confounding. Multicollinearity among covariates was assessed using variance inflation factors, and no evidence of problematic multicollinearity was identified. Model fit was evaluated using the Hosmer–Lemeshow goodness-of-fit test. Model discrimination was assessed using the C-statistic (area under the receiver operating characteristic curve). Calibration was evaluated by comparing observed and predicted event rates across deciles of predicted risk. P value < 0.05 was considered as statistically significant. Statistical Package for Social Sciences, version 25 (IBM SPSS Inc, Armonk, NY, USA) was used for data analysis. Ethical considerations This study was approved by the National Ethics Committee for Health Research in Lao PDR on March 14, 2023 (approval number: 16/NECHR). Informed consent was waived because COVID-19 case registration was conducted as part of national quarantine measures. This study was conducted in accordance with the Declaration of Helsinki. Results The epidemiological trends of COVID-19 from 2020 to 2021 in Lao PDR From January 2020 to December 2021, 1,408,839 suspected cases had tests for COVID-19, 114,434 cases were confirmed positive, and 162 cases died. The first confirmed case and death were reported in the 13th epi-week of 2020 and 10th epi-week of 2021, respectively (Fig. 1). The total number of confirmed cases was 4,973 in 2020 and 109,461 in 2021. The number of confirmed cases greatly increased in the beginning of 2021 and constantly increased from the 14th epi-week of 2021. The annual cumulative confirmed case rate was 67.7 per 100,000 population in 2020 and 1,468.6 per 100,000 population in 2021. There were no deaths in 2020 and 162 deaths in 2021. The cumulative number of laboratory-confirmed SARS-CoV-2 cases over the two-year period was 1,546.3 per 100,000 population and the overall CFR was 0.14%. Fig. 1Number of COVID-19 confirmed cases and deaths due to COVID-19 and the case fatality rate in each epi-week from 2020 to 2021. The bars represent the number of confirmed cases (blue) and deaths (red) reported each epidemiological week. The yellow solid line indicates the case fatality rate, calculated as the number of deaths divided by the number of confirmed cases for each week. The primary y-axis indicates the number of confirmed cases and deaths, while the secondary y-axis represents the case fatality rate Number of COVID-19 confirmed cases and deaths due to COVID-19 and the case fatality rate in each epi-week from 2020 to 2021. The bars represent the number of confirmed cases (blue) and deaths (red) reported each epidemiological week. The yellow solid line indicates the case fatality rate, calculated as the number of deaths divided by the number of confirmed cases for each week. The primary y-axis indicates the number of confirmed cases and deaths, while the secondary y-axis represents the case fatality rate Socio-demographic characteristics of COVID-19 confirmed cases Socio-demographic characteristics of 114,434 confirmed cases showed that males accounted for 53.5% and the major age group was 20–29 years old (34.1%) followed by 30–39 years old (25.3%) (Table 1). Most cases were Laotian and 2.2% of all cases were foreigners. The major occupation was NGO employees (32.6%) followed by students (18.0%) and unemployed (16.8%). Most cases were from the central region (64.1%). Table 1Socio-demographic factors of COVID-19 cases (N = 114,434)VariablesAsymptomatic case(n = 94,341)Mild case(n = 18,858)Severe case(n = 1,235)Total(N = 114,434)n (%)an (%)an (%)aN (%)b Sex Male50,468 (82.5)9,948 (16.3)762 (1.2)61,178 (53.5) Female43,873 (82.4)8,910 (16.7)473 (0.9)53,256 (46.5) Age (years old) 0–97,706 (87.1)1,074 (12.1)66 (0.8)8,846 (7.7) 10–1910,844 (83.3)2,076 (15.9)99 (0.8)13,019 (11.4) 20–2932,072 (82.1)6,622 (17.0)363 (0.9)39,057 (34.1) 30–3923,563 (81.3)5,120 (17.6)317 (1.1)29,000 (25.3) 40–499,986 (82.0)2,055 (16.8)142 (1.2)12,183 (10.6) 50–595,688 (82.4)1,106 (16.0)112 (1.6)6,906 (6.0) 60–692,876 (83.5)506 (14.6)64 (1.9)3,446 (3.0) ≥ 701,606 (81.2)299 (15.2)72 (3.6)1,977 (1.7) Nationality Laotian92,042 (82.2)18,703 (16.7)1,225 (1.1)111,970 (97.8) Asian2,252 (93.8)140 (5.8)9 (2.5)2,401 (2.2) European28 (70.0)11 (27.5)1 (2.5)40 (0.0) North/South American12 (92.3)1 (7.7)0 (0.0)13 (0.0) African1 (100.0)0 (0.0)0 (0.0)1 (0.0) Australian and Pacific Islander6 (70.0)3 (30.0)0 (0.0)9 (0.0) Occupation Unemployed16,049 (83.7)2,896 (15.1)228 (1.2)19,173 (16.8) NGO employee30,507 (81.8)6,349 (17.0)427 (1.1)37,283 (32.6) Government employee6,237 (79.2)1,552 (19.7)85 (1.1)7,874 (6.9) Factory worker5,854 (81.6)1,260 (17.6)61 (0.9)8,437 (7.4) Security worker7,121 (75.3)2,240 (23.7)94 (1.0)9,455 (8.3) Healthcare worker1,840 (74.7)590 (24.0)33 (1.3)2,463 (2.2) Teacher1,947 (96.0)75 (3.7)6 (0.3)2,028 (1.8) Returnee worker1,230 (97.5)30 (2.4)2 (0.2)1,262 (1.1) Monk418 (88.4)49 (10.4)6 (1.3)473 (0.3) Prisoner5,196 (85.2)784 (12.9)121 (2.0)6,101 (5.3) Student17,456 (84.9)2,940 (14.3)166 (0.8)20,562 (18.0) Dependent486 (83.1)93 (15.9)6 (1.0)585 (0.5) Region Central58,518 (79.8)14,048 (19.2)744 (1.0)73,310 (64.1) Northern25,402 (86.2)3,661 (12.4)425 (1.4)29,488 (25.8) Southern10,421 (89.6)1,149 (9.8)66 (0.6)11,636 (10.1)NGO, non-governmental organizationaPercentages are calculated by row and represent the distribution of characteristics within each category groupbPercentages are calculated by column Table 1Socio-demographic factors of COVID-19 cases (N = 114,434)VariablesAsymptomatic case(n = 94,341)Mild case(n = 18,858)Severe case(n = 1,235)Total(N = 114,434)n (%)an (%)an (%)aN (%)b Sex Male50,468 (82.5)9,948 (16.3)762 (1.2)61,178 (53.5) Female43,873 (82.4)8,910 (16.7)473 (0.9)53,256 (46.5) Age (years old) 0–97,706 (87.1)1,074 (12.1)66 (0.8)8,846 (7.7) 10–1910,844 (83.3)2,076 (15.9)99 (0.8)13,019 (11.4) 20–2932,072 (82.1)6,622 (17.0)363 (0.9)39,057 (34.1) 30–3923,563 (81.3)5,120 (17.6)317 (1.1)29,000 (25.3) 40–499,986 (82.0)2,055 (16.8)142 (1.2)12,183 (10.6) 50–595,688 (82.4)1,106 (16.0)112 (1.6)6,906 (6.0) 60–692,876 (83.5)506 (14.6)64 (1.9)3,446 (3.0) ≥ 701,606 (81.2)299 (15.2)72 (3.6)1,977 (1.7) Nationality Laotian92,042 (82.2)18,703 (16.7)1,225 (1.1)111,970 (97.8) Asian2,252 (93.8)140 (5.8)9 (2.5)2,401 (2.2) European28 (70.0)11 (27.5)1 (2.5)40 (0.0) North/South American12 (92.3)1 (7.7)0 (0.0)13 (0.0) African1 (100.0)0 (0.0)0 (0.0)1 (0.0) Australian and Pacific Islander6 (70.0)3 (30.0)0 (0.0)9 (0.0) Occupation Unemployed16,049 (83.7)2,896 (15.1)228 (1.2)19,173 (16.8) NGO employee30,507 (81.8)6,349 (17.0)427 (1.1)37,283 (32.6) Government employee6,237 (79.2)1,552 (19.7)85 (1.1)7,874 (6.9) Factory worker5,854 (81.6)1,260 (17.6)61 (0.9)8,437 (7.4) Security worker7,121 (75.3)2,240 (23.7)94 (1.0)9,455 (8.3) Healthcare worker1,840 (74.7)590 (24.0)33 (1.3)2,463 (2.2) Teacher1,947 (96.0)75 (3.7)6 (0.3)2,028 (1.8) Returnee worker1,230 (97.5)30 (2.4)2 (0.2)1,262 (1.1) Monk418 (88.4)49 (10.4)6 (1.3)473 (0.3) Prisoner5,196 (85.2)784 (12.9)121 (2.0)6,101 (5.3) Student17,456 (84.9)2,940 (14.3)166 (0.8)20,562 (18.0) Dependent486 (83.1)93 (15.9)6 (1.0)585 (0.5) Region Central58,518 (79.8)14,048 (19.2)744 (1.0)73,310 (64.1) Northern25,402 (86.2)3,661 (12.4)425 (1.4)29,488 (25.8) Southern10,421 (89.6)1,149 (9.8)66 (0.6)11,636 (10.1)NGO, non-governmental organizationaPercentages are calculated by row and represent the distribution of characteristics within each category groupbPercentages are calculated by column Socio-demographic factors of COVID-19 cases (N = 114,434) NGO, non-governmental organization aPercentages are calculated by row and represent the distribution of characteristics within each category group bPercentages are calculated by column Clinical data of COVID-19 confirmed cases Of all the 114,434 confirmed cases, 95.7% were registered in 2021 and 97.7% had no comorbidity (Table 2). The major source of infection was close contact (60.3%) followed by unlinked sources (22.6%) and travel-related sources (12.8%). Vaccination status showed that 52.4% of cases had received three or more doses, while 8.9% had no vaccination. All 1,235 severe cases were hospitalized and 57 cases stayed in hospitals for more than seven days. There were 162 dead cases, who were all severe cases. The CFR was 0.14% among all cases and 13.1% among severe cases. Table 2Clinical factors of COVID-19 cases (N = 114,434)VariablesAsymptomatic case(n = 94,341)Mild case(n = 18,858)Severe case(n = 1,235)Total(N = 114,434)n (%)an (%)an (%)aN (%)b Registration year 20204,604 (92.6)341 (6.9)28 (0.6)4,973 (4.3) 202189,737 (82.0)18,517 (16.9)1,207 (1.1)109,461 (95.7) Number of comorbidities 092,626 (82.9)18,057 (16.2)1,097 (1.0)111,780 (97.7) 11,506 (64.5)734 (31.4)96 (4.1)2,336 (2.0) ≥ 2209 (65.7)67 (21.1)42 (13.2)318 (0.3) Source of infection Close contact52,930 (76.7)15,125 (21.9)929 (1.4)68,984 (60.3) Exposure to high-risk settings3,688 (74.8)1,155 (23.4)87 (1.8)4,930 (4.3) Travel-related13,795 (94.2)776 (5.3)66 (0.5)14,637 (12.8) Unlinked23,928 (92.4)1,802 (7.0)153 (0.6)25,883 (22.6) Vaccination dose 0 dose8,371 (82.2)1,725 (16.9)96 (0.9)10,192 (8.9) 1 dose2,303 (65.1)1,195 (33.8)42 (1.1)3,540 (3.1) 2 doses29,849 (73.3)10,434 (25.6)441 (1.1)40,724 (35.6) ≥ 3 doses53,818 (89.7)5,504 (9.2)656 (1.1)59,978 (52.4) Hospitalization No94,341 (83.3)18,858 (16.7)0 (0.0)113,199 (98.9) 1–7 days0 (0.0)0 (0.0)1,178 (100.0)1,178 (1.1) > 7 days0 (0.0)0 (0.0)57 (100.0)57 (0.0) Outcome Alive94,341 (82.6)18,858 (16.5)1,073 (0.9)114,272 (99.9) Dead0 (0.0)0 (0.0)162 (100.0)162 (0.1)NGO, non-governmental organizationaPercentages are calculated by row and represent the distribution of characteristics within each category groupbPercentages are calculated by column Table 2Clinical factors of COVID-19 cases (N = 114,434)VariablesAsymptomatic case(n = 94,341)Mild case(n = 18,858)Severe case(n = 1,235)Total(N = 114,434)n (%)an (%)an (%)aN (%)b Registration year 20204,604 (92.6)341 (6.9)28 (0.6)4,973 (4.3) 202189,737 (82.0)18,517 (16.9)1,207 (1.1)109,461 (95.7) Number of comorbidities 092,626 (82.9)18,057 (16.2)1,097 (1.0)111,780 (97.7) 11,506 (64.5)734 (31.4)96 (4.1)2,336 (2.0) ≥ 2209 (65.7)67 (21.1)42 (13.2)318 (0.3) Source of infection Close contact52,930 (76.7)15,125 (21.9)929 (1.4)68,984 (60.3) Exposure to high-risk settings3,688 (74.8)1,155 (23.4)87 (1.8)4,930 (4.3) Travel-related13,795 (94.2)776 (5.3)66 (0.5)14,637 (12.8) Unlinked23,928 (92.4)1,802 (7.0)153 (0.6)25,883 (22.6) Vaccination dose 0 dose8,371 (82.2)1,725 (16.9)96 (0.9)10,192 (8.9) 1 dose2,303 (65.1)1,195 (33.8)42 (1.1)3,540 (3.1) 2 doses29,849 (73.3)10,434 (25.6)441 (1.1)40,724 (35.6) ≥ 3 doses53,818 (89.7)5,504 (9.2)656 (1.1)59,978 (52.4) Hospitalization No94,341 (83.3)18,858 (16.7)0 (0.0)113,199 (98.9) 1–7 days0 (0.0)0 (0.0)1,178 (100.0)1,178 (1.1) > 7 days0 (0.0)0 (0.0)57 (100.0)57 (0.0) Outcome Alive94,341 (82.6)18,858 (16.5)1,073 (0.9)114,272 (99.9) Dead0 (0.0)0 (0.0)162 (100.0)162 (0.1)NGO, non-governmental organizationaPercentages are calculated by row and represent the distribution of characteristics within each category groupbPercentages are calculated by column Clinical factors of COVID-19 cases (N = 114,434) NGO, non-governmental organization aPercentages are calculated by row and represent the distribution of characteristics within each category group bPercentages are calculated by column Symptoms and COVID-19 severity Of all the 114,434 confirmed cases, 3.3% had a fever, 3.0% had a cough, 8.0% had a sore throat, 5.5% had a runny nose, 1.1% had dyspnea, and 3.7% had loss of smell or taste (Table 3). All cases were classified into asymptomatic (n = 94,341; 82.4%), mild (n = 18,858; 16.5%), and severe (n = 1,235; 1.1%) groups according to COVID-19 severity (Tables 1 and 2). Table 3Symptoms of COVID-19 confirmed casesSymptomsMild case(n = 18,858)Severe case(n = 1,235)Total(N = 114,434)n (%)n (%)N (%)Fever3,555 (18.9)264 (21.4)3,819 (3.3)Cough3,169 (16.8)260 (21.1)3,429 (3.0)Sore throat8,604 (45.6)538 (43.6)9,142 (8.0)Runny nose6,027 (32.0)282 (22.8)6,309 (5.5)Dyspnea0 (0.0)1,235 (100.0)1,235 (1.1)Loss of smell or taste3,937 (20.9)258 (20.9)4,195 (3.7)Percentages are calculated within mild cases, severe cases, and total cases Table 3Symptoms of COVID-19 confirmed casesSymptomsMild case(n = 18,858)Severe case(n = 1,235)Total(N = 114,434)n (%)n (%)N (%)Fever3,555 (18.9)264 (21.4)3,819 (3.3)Cough3,169 (16.8)260 (21.1)3,429 (3.0)Sore throat8,604 (45.6)538 (43.6)9,142 (8.0)Runny nose6,027 (32.0)282 (22.8)6,309 (5.5)Dyspnea0 (0.0)1,235 (100.0)1,235 (1.1)Loss of smell or taste3,937 (20.9)258 (20.9)4,195 (3.7)Percentages are calculated within mild cases, severe cases, and total cases Symptoms of COVID-19 confirmed cases Percentages are calculated within mild cases, severe cases, and total cases Factors associated with severe COVID-19 Logistic regression analyses were conducted to identify factors associated with severe disease. In binary logistic regression, sex, age group, nationality, occupation, region, source of infection, and comorbidities were associated with severe cases (Table 4). In the multivariable logistic regression analysis, male sex (adjusted odds ratio [AOR] = 1.43, 95% CI: 1.26–1.62); age 30–39 years (AOR = 1.44, 95% CI:1.05–1.98), 50–59 years (AOR = 1.74, 95% CI: 1.22–2.47), 60–69 years (AOR = 2.01, 95% CI: 1.36–2.97), and ≥ 70 years (AOR = 4.10, 95% CI: 2.78–6.04) (vs. 0–9 years); Laotian nationality (vs. foreigner; AOR = 4.42, 95% CI: 2.34–8.36); NGO employees (AOR = 1.30, 95% CI: 1.08–1.58) and prisoners (AOR = 1.76, 95% CI: 1.36–2.25) (vs. unemployed); residence in the northern region (vs. the central region; AOR = 1.78, 95% CI: 1.56–2.03), and presence of comorbidities (AOR = 4.43, 95% CI: 3.62–5.42) were associated with severe COVID-19. Teachers were negatively associated with severe COVID-19 (AOR = 0.40, 95% CI: 0.17–0.89) compared to unemployed. Regarding the source of infection, exposure in high-risk settings was associated with severe disease compared with close contact (AOR = 1.29, 95% CI: 1.02–1.62), whereas travel-related (AOR = 0.48, 95% CI: 0.37–0.63) and unlinked cases (AOR = 0.39, 95% CI: 0.32–0.46) were less likely to be severe. Vaccination dose was not significantly associated with severe COVID-19 among all confirmed cases. The model demonstrated acceptable discrimination, with a C-statistic (area under the receiver operating characteristic curve) of 0.681 (95% CI: 0.665–0.697). Although the Hosmer–Lemeshow test was statistically significant (P < 0.001), calibration across deciles of predicted risk showed good agreement between observed and predicted event rates, with only minor deviation at higher risk levels, indicating overall acceptable model performance. Table 4Logistic regression analysis on severe cases (N = 114,434)VariablesOR (95% CI)P-valueAOR (95% CI)aP-value Sex Male1.41 (1.25–1.58)< 0.0011.43 (1.26–1.62)< 0.001 Female1 (Reference)1 (Reference) Age (years old) 0–91 (Reference)1 (Reference) 10–191.02 (0.75–1.40)0.9040.99 (0.71–1.36)0.940 20–291.24 (0.96–1.62)0.0991.28 (0.94–1.73)0.109 30–391.47 (1.12–1.91)0.0051.44 (1.05–1.98)0.022 40–491.57 (1.17–2.10)0.0031.38 (0.98–1.94)0.062 50–592.19 (1.61–2.98)< 0.0011.74 (1.22–2.47)0.002 60–692.51 (1.79–3.56)< 0.0012.01 (1.36–2.97)< 0.001 ≥ 705.02 (3.59–7.04)< 0.0014.10 (2.78–6.04)< 0.001 Nationality Laotian2.71 (1.45–5.06)0.0024.42 (2.34–8.36)< 0.001 Foreigner1 (Reference)1 (Reference) Occupation Unemployed1 (Reference)1 (Reference) NGO employee0.97 (0.81–1.13)0.6451.30 (1.08–1.58)0.005 Government employee0.90 (0.70–1.16)0.4441.00 (0.76–1.31)0.992 Factory worker0.71 (0.53–0.94)0.0191.24 (0.91–1.70)0.164 Security worker0.83 (0.66–1.06)0.1420.94 (0.72–1.23)0.675 Healthcare worker1.12 (0.78–1.63)0.5191.30 (0.88–1.89)0.190 Teacher0.24 (0.10–0.56)0.0010.40 (0.17–0.89)0.025 Returnee worker0.13 (0.03–0.53)0.0040.32 (0.07–1.31)0.113 Monk1.06 (0.48–2.41)0.8751.24 (0.54–2.87)0.608 Prisoner1.69 (1.34–2.10)< 0.0011.76 (1.36–2.25)< 0.001 Student0.67 (0.56–0.82)< 0.0011.12 (0.88–1.43)0.330 Dependent0.86 (0.38–1.94)0.7191.67 (0.70–3.94)0.246 Region Central1 (Reference)1 (Reference) Northern1.43 (1.27–1.61)< 0.0011.78 (1.56–2.03)< 0.001 Southern0.56 (0.43–0.72)< 0.0010.67 (0.52–0.87)0.002 Source of infection Close contact1 (Reference)1 (Reference) Exposure to high-risk setting1.32 (1.05–1.64)0.0151.29 (1.02–1.62)0.031 Travel-related0.33 (0.26–0.43)< 0.0010.48 (0.37–0.63)< 0.001 Unlinked0.44 (0.37–0.52)< 0.0010.39 (0.32–0.46)< 0.001 Comorbidity No1 (Reference)1 (Reference) Yes5.53 (4.62–6.63)< 0.0014.43 (3.62–5.42)< 0.001 Vaccination dose 0 dose1 (Reference)1 (Reference) 1 dose1.26 (0.88–1.82)0.2101.00 (0.69–1.44)1.000 2 doses1.15 (0.92–1.44)0.2130.90 (0.72–1.14)0.408 ≥ 3 doses1.16 (0.94–1.44)0.1691.04 (0.83–1.30)0.693OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; NGO, non-governmental organizationaAdjusted for sex, age, nationality, occupation, region, source of infection, comorbidity, and vaccination dose Table 4Logistic regression analysis on severe cases (N = 114,434)VariablesOR (95% CI)P-valueAOR (95% CI)aP-value Sex Male1.41 (1.25–1.58)< 0.0011.43 (1.26–1.62)< 0.001 Female1 (Reference)1 (Reference) Age (years old) 0–91 (Reference)1 (Reference) 10–191.02 (0.75–1.40)0.9040.99 (0.71–1.36)0.940 20–291.24 (0.96–1.62)0.0991.28 (0.94–1.73)0.109 30–391.47 (1.12–1.91)0.0051.44 (1.05–1.98)0.022 40–491.57 (1.17–2.10)0.0031.38 (0.98–1.94)0.062 50–592.19 (1.61–2.98)< 0.0011.74 (1.22–2.47)0.002 60–692.51 (1.79–3.56)< 0.0012.01 (1.36–2.97)< 0.001 ≥ 705.02 (3.59–7.04)< 0.0014.10 (2.78–6.04)< 0.001 Nationality Laotian2.71 (1.45–5.06)0.0024.42 (2.34–8.36)< 0.001 Foreigner1 (Reference)1 (Reference) Occupation Unemployed1 (Reference)1 (Reference) NGO employee0.97 (0.81–1.13)0.6451.30 (1.08–1.58)0.005 Government employee0.90 (0.70–1.16)0.4441.00 (0.76–1.31)0.992 Factory worker0.71 (0.53–0.94)0.0191.24 (0.91–1.70)0.164 Security worker0.83 (0.66–1.06)0.1420.94 (0.72–1.23)0.675 Healthcare worker1.12 (0.78–1.63)0.5191.30 (0.88–1.89)0.190 Teacher0.24 (0.10–0.56)0.0010.40 (0.17–0.89)0.025 Returnee worker0.13 (0.03–0.53)0.0040.32 (0.07–1.31)0.113 Monk1.06 (0.48–2.41)0.8751.24 (0.54–2.87)0.608 Prisoner1.69 (1.34–2.10)< 0.0011.76 (1.36–2.25)< 0.001 Student0.67 (0.56–0.82)< 0.0011.12 (0.88–1.43)0.330 Dependent0.86 (0.38–1.94)0.7191.67 (0.70–3.94)0.246 Region Central1 (Reference)1 (Reference) Northern1.43 (1.27–1.61)< 0.0011.78 (1.56–2.03)< 0.001 Southern0.56 (0.43–0.72)< 0.0010.67 (0.52–0.87)0.002 Source of infection Close contact1 (Reference)1 (Reference) Exposure to high-risk setting1.32 (1.05–1.64)0.0151.29 (1.02–1.62)0.031 Travel-related0.33 (0.26–0.43)< 0.0010.48 (0.37–0.63)< 0.001 Unlinked0.44 (0.37–0.52)< 0.0010.39 (0.32–0.46)< 0.001 Comorbidity No1 (Reference)1 (Reference) Yes5.53 (4.62–6.63)< 0.0014.43 (3.62–5.42)< 0.001 Vaccination dose 0 dose1 (Reference)1 (Reference) 1 dose1.26 (0.88–1.82)0.2101.00 (0.69–1.44)1.000 2 doses1.15 (0.92–1.44)0.2130.90 (0.72–1.14)0.408 ≥ 3 doses1.16 (0.94–1.44)0.1691.04 (0.83–1.30)0.693OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; NGO, non-governmental organizationaAdjusted for sex, age, nationality, occupation, region, source of infection, comorbidity, and vaccination dose Logistic regression analysis on severe cases (N = 114,434) OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; NGO, non-governmental organization aAdjusted for sex, age, nationality, occupation, region, source of infection, comorbidity, and vaccination dose Exploratory subgroup analysis of severe COVID-19 among vaccinated cases, by vaccine type and number of doses As an exploratory analysis, we further examined the proportion of severe cases among vaccinated cases only (n = 104,242), stratified by vaccine type and number of doses (Table 5). BBIBP-CorV was the most frequently administered vaccine (n = 32,286), followed by a heterologous combination of ChAdOx1 nCoV-19 and BBIBP-CorV (n = 22,661). Among cases who had received a single vaccine type, a lower proportion of severe cases was observed among those who had received three or more doses compared with those who had received one or two doses across several vaccine platforms, including viral vector, mRNA, and inactivated virus vaccines. A similar pattern was observed when vaccine platforms were grouped by type. In contrast, among cases who had received three or more doses involving two different vaccines or two vaccine types, the proportion of severe cases tended to be higher than that observed among those who had received a single vaccine product or a single vaccine platform. Overall, the proportion of severe cases among cases who had received three or more doses was similar to that among those had received one or two doses. Notably, the absolute number of severe cases in each subgroup was small, and these comparisons were not adjusted for differences in underlying risk profiles or potential confounding factors; therefore, these findings should be interpreted with caution. Table 5Descriptive exploratory subgroup analysis of severe COVID-19 among vaccinated cases, by vaccine type and number of doses (N = 104,242)Total1–2 doses3 or more dosesTotalSevere caseTotalSevere case N n (%) N n (%) Vaccine ChAdOx1 nCoV-1913,9786,47448 (0.7%)7,50411 (0.1%) Ad26.COV2.S2,9972,99438 (1.3%)30 (0.0%) BNT162b213,5994,18055 (1.3%)9,41933 (0.4%) BBIBP-CorV32,28628,715301 (1.0%)3,5716 (0.2%) CoronaVac54540 (0.0%)-- Gam-COVID-Vac27240 (0.0%)30 (0.0%) ChAdOx1 nCoV-19 + Ad26.COV2.S1,2191,21931 (2.5%)-- ChAdOx1 nCoV-19 + BNT162b213,415--13,415163 (1.2%) ChAdOx1 nCoV-19 + BBIBP-CorV22,661--22,661421 (1.9%) Ad26.COV2.S + BNT162b260460410 (1.7%)-- BNT162b2 + BBIBP-CorV3,402--3,40222 (0.6%) Type of vaccines a mRNA13,5994,18055 (1.3%)9,41933 (0.4%) Viral vector18,22110,711117 (1.1%)7,51011 (0.1%) Inactivated virus32,34028,769301 (1.0%)3,5716 (0.2%) mRNA + viral vector14,01960410 (1.7%)13,415163 (1.2%) mRNA + inactivated virus3,402--3,40222 (0.6%) Viral vector + inactivated virus22,661--22,661421 (1.9%)Total104,24244,264483 (1.1%)59,978656 (1.1%)amRNA includes BNT162b2, viral vector vaccine includes ChAdOx1 nCoV-19, Ad26.COV2.S, and Gam-COVID-Vac, and inactivated virus vaccine includes BBIBP-CorV and CoronaVacValues are presented as number (%), where percentages represent the proportion of severe cases within each vaccination subgroup (row percentages) Table 5Descriptive exploratory subgroup analysis of severe COVID-19 among vaccinated cases, by vaccine type and number of doses (N = 104,242)Total1–2 doses3 or more dosesTotalSevere caseTotalSevere case N n (%) N n (%) Vaccine ChAdOx1 nCoV-1913,9786,47448 (0.7%)7,50411 (0.1%) Ad26.COV2.S2,9972,99438 (1.3%)30 (0.0%) BNT162b213,5994,18055 (1.3%)9,41933 (0.4%) BBIBP-CorV32,28628,715301 (1.0%)3,5716 (0.2%) CoronaVac54540 (0.0%)-- Gam-COVID-Vac27240 (0.0%)30 (0.0%) ChAdOx1 nCoV-19 + Ad26.COV2.S1,2191,21931 (2.5%)-- ChAdOx1 nCoV-19 + BNT162b213,415--13,415163 (1.2%) ChAdOx1 nCoV-19 + BBIBP-CorV22,661--22,661421 (1.9%) Ad26.COV2.S + BNT162b260460410 (1.7%)-- BNT162b2 + BBIBP-CorV3,402--3,40222 (0.6%) Type of vaccines a mRNA13,5994,18055 (1.3%)9,41933 (0.4%) Viral vector18,22110,711117 (1.1%)7,51011 (0.1%) Inactivated virus32,34028,769301 (1.0%)3,5716 (0.2%) mRNA + viral vector14,01960410 (1.7%)13,415163 (1.2%) mRNA + inactivated virus3,402--3,40222 (0.6%) Viral vector + inactivated virus22,661--22,661421 (1.9%)Total104,24244,264483 (1.1%)59,978656 (1.1%)amRNA includes BNT162b2, viral vector vaccine includes ChAdOx1 nCoV-19, Ad26.COV2.S, and Gam-COVID-Vac, and inactivated virus vaccine includes BBIBP-CorV and CoronaVacValues are presented as number (%), where percentages represent the proportion of severe cases within each vaccination subgroup (row percentages) Descriptive exploratory subgroup analysis of severe COVID-19 among vaccinated cases, by vaccine type and number of doses (N = 104,242) amRNA includes BNT162b2, viral vector vaccine includes ChAdOx1 nCoV-19, Ad26.COV2.S, and Gam-COVID-Vac, and inactivated virus vaccine includes BBIBP-CorV and CoronaVac Values are presented as number (%), where percentages represent the proportion of severe cases within each vaccination subgroup (row percentages) Discussion This nationwide study showed that the cumulative number of laboratory-confirmed SARS-CoV-2 cases was 1,546.3 per 100,000 population and the CFR was 0.14% during the first two years of the COVID-19 pandemic in Lao PDR. Most confirmed cases were young adults, Laotian, residents in the central region, and asymptomatic. The major source of infection was close contact, 2.3% had comorbidities, and 52.4% received three or more doses of vaccinations. In multivariable analyses, male sex, older age, Laotian, employment as an NGO worker or prisoner, residence in the northern region, exposure in high-risk settings, and the presence of comorbidity were associated with severe COVID-19; however, the very low absolute number of severe cases likely limited the precision of these estimates. In addition, the rapid increase in confirmed cases in 2021 temporally overlapped with the reported emergence of the Alpha and subsequently Delta variants in Lao PDR, as reported in World Health Organization situation reports [26]; however, variant identification was conducted in a limited number of samples and was not included in the present analysis. The low percentage of foreigners and travel-related cases among COVID-19 cases may reflect the early implementation of border control measures and travel restrictions, although the effectiveness of these policies was not directly evaluated in this study. The relatively low proportion of severe cases observed in this study may reflect a combination of contextual and individual-level factors, including a relatively low population density [27], the predominance of younger individuals [14], and the low prevalence of comorbidities among reported cases [15]. The predominance of young and healthy adults among reported COVID-19 cases may be explained by several contextual factors. In this study, cases aged 20–39 years accounted for 59.4% of confirmed cases, whereas those aged 60 years or older represented only 4.7%; in contrast, these age groups constitute 29.8% and 9.5% of the general population, respectively [28]. This discrepancy suggests lower detection or exposure among older adults, potentially due to reduced mobility or targeted protective behaviors, although infection rates by age were not directly assessed. In addition, the observed low incidence and low proportion of severe cases may be attributable to genuinely limited viral spread in the community, under-detection of infections, or a combination of both. Limited testing capacity, asymptomatic infections, and barriers to healthcare access may have resulted in underreporting, as observed in many LMICs [29, 30]. Conversely, serological evidence suggests that SARS-CoV-2 circulation in Lao PDR was limited during the early phase of the pandemic [4]. Importantly, this study focused on individual-level characteristics of reported cases rather than an evaluation of national-level determinants of COVID-19 severity; therefore, it could not determine the relative contribution of these explanations. Previous studies reported that not only the incidence of severe disease but also the mortality rate was higher among male COVID-19 cases than female cases [16, 17]. It may be explained by a combination of biological, immunological, and behavioral differences among sexes [31, 32]. Females generally have stronger innate and adaptive immune responses due to hormonal and genetic factors [17, 33]. Males are more likely to have pre-existing conditions such as hypertension, cardiovascular disease, and diabetes, which are associated with worse COVID-19 outcomes [16]. Higher smoking and alcohol consumption rates among males may contribute to lung damage and a weakened immune system, increasing the risk of severe disease, although an association between such behaviors and severe COVID-19 was not examined in the present study. Meta-analyses of SARS-CoV-2 infections demonstrated that the risk of severe and critical illness increases exponentially with age, especially among individuals over 60 years old, and comorbidities [14, 15]. In high-risk environments such as hospitals and prisons, older adults and those with pre-existing health conditions are more susceptible to severe outcomes from COVID-19. The close contact in these settings increases the risk of severe disease progression [19]. Teachers might have a lower risk than the general population because school closures during lockdown periods substantially reduced occupational exposure and close-contact interactions, thereby limiting cumulative viral exposure [34]. Studies have also shown that healthcare workers and inpatients, as well as prisoners, are at a higher risk of severe illness due to exposure to high viral loads and the vulnerability of the populations [18, 19]. In contrast, travel-related and unlinked cases tend to be less severe. It has been suggested that unlinked cases often exhibit longer intervals from symptom onset to hospital admission and a lower proportion of critical illness, indicating milder infections [35]. Additionally, these cases tend to have higher median cycle threshold values, reflecting lower viral loads at presentation, which correlates with reduced disease severity [35]. The strong association observed between Lao nationality and severe COVID-19 should be interpreted cautiously. This finding is likely influenced by surveillance and selection biases rather than reflecting a true causal effect of nationality. Foreign residents in Lao PDR during the study period often had better access to healthcare services, earlier testing, and isolation facilities, whereas Lao nationals were more likely to be detected through routine surveillance or to present at healthcare facilities when symptoms were already advanced. Moreover, differences in health-seeking behavior and under-ascertainment of mild infections among Lao nationals may have contributed to an overestimation of the association. Thus, nationality in this study likely serves as a proxy for structural, social, and healthcare access disparities rather than an intrinsic risk factor for severe disease. This study showed a distinct geographical pattern in the risk of developing severe COVID-19, with the northern region of Lao PDR exhibiting the highest risk. This disparity may be linked to socioeconomic and environmental factors. The northern region has the highest share of households in the poorest wealth quintile, the largest proportion of illiterate women, the highest smoking and drinking rate among men, and the most migrants [28]. Poverty limits access to healthcare, nutritious food, and essential resources, while low literacy hampers understanding of health information and adherence to public health measures [36–38]. Moreover, the northern region faces the most severe and prolonged air pollution from seasonal biomass burning, unlike the central and southern regions, which report lower levels [39]. This correlation between elevated air pollution exposure and disease severity suggests that air pollution may act as an effect modifier. Chronic or acute exposure to hazardous air quality, particularly during the haze season (the dry season in Southeast Asia characterized by severe air pollution from biomass burning), may impair respiratory and immune functions, raising susceptibility to severe illness from SARS-CoV-2 infection [40]. Multiple studies and meta-analyses, including those from Southeast Asia and worldwide, have reported that COVID-19 vaccination effectively reduces the risk of severe disease [20, 21]. Factors reported to be associated with reduced vaccine effectiveness include longer time since vaccination, use of viral vector vaccines compared to mRNA vaccines, incomplete vaccination schedule, older age (> 65 years), and the presence of comorbidities [20, 41]. Previous studies have also suggested that heterologous vaccination may induce stronger immune responses than homologous vaccination [42]. In our study, a lower proportion of severe disease was observed among cases receiving three or more doses of homologous vaccines in an exploratory analysis, whereas no similar pattern was observed for heterologous vaccination or in the overall analysis including all cases. These findings should be interpreted cautiously due to the exploratory nature of the analysis and the small number of severe cases. In addition, these vaccination-related findings are subject to residual confounding and calendar-time bias, as vaccination dose, vaccine type, and eligibility were closely linked to the timing of infection, circulating SARS-CoV-2 variants, and risk-based vaccination policies during the study period. The observed patterns may reflect contextual factors specific to the vaccine strategy in Lao PDR. During the study period, mixed vaccine schedules were predominantly administered to individuals considered to be at a higher risk of exposure, such as frontline healthcare workers and border or airport personnel. Consistent with this policy, a substantial proportion of government officers and prisoners received heterologous vaccination, i.e., populations that may have experienced higher exposure risk. In addition, differences in vaccine platform, dosing intervals, and circulating SARS-CoV-2 variants may influence comparative vaccine effectiveness, although these factors could not be evaluated in the present analysis. Taken together, our findings do not contradict the established protective effect of COVID-19 vaccination but rather highlight the challenges of interpreting vaccine effectiveness using surveillance-based data in settings with low numbers of severe outcomes. Severe cases observed among partially vaccinated cases should also be interpreted cautiously, as vaccination does not completely eliminate the risk of severe disease, particularly in the presence of unmeasured confounders and waning immunity. There are some limitations to this study. First, this study was based on a national surveillance system and is therefore subject to surveillance bias and limited clinical detail. Disease severity was defined using national surveillance criteria and assessed based on symptom reports at the time of case confirmation, rather than detailed hospital records or clinician-evaluated severity scores. Owing to limited healthcare workforce capacity during the pandemic, systematic clinical follow-up was not feasible, and disease progression after registration could not be identified. These factors may have resulted in misclassification and limited precision in severity assessment. Second, the reported case rate and CFR in this study may be underestimated due to underreporting. Asymptomatic cases who did not seek testing and COVID-19-related deaths, especially those occurring outside healthcare settings or in remote areas, may not have been fully captured [43]. In addition, the low number of severe cases limited the number of events per variable, which may have reduced statistical power and the stability of multivariable estimates. Third, the contribution of SARS-CoV-2 variants to disease severity could not be evaluated. Variant identification was performed only in selected cases under national surveillance criteria and was not available for the majority of confirmed cases, precluding variant-specific analysis. Fourth, detailed information of vaccination, such as the date of vaccinations and doses of each vaccine were not collected. Although vaccination status reflected doses received prior to case confirmation, we were unable to assess time since last dose, calendar-time effects, or waning immunity, which may have introduced residual confounding in analyses of vaccination and disease severity. Finally, the higher risk of severe disease observed among Lao nationals compared with foreigners may reflect a healthy traveler bias and differences in surveillance intensity and healthcare access. Foreigners were often detected through international travel surveillance and likely had better access to testing, whereas Lao nationals included vulnerable populations in remote settings, where cases may have been registered only after progression to severe illness. Conclusion This nationwide study in Lao PDR demonstrates that while the overall number of COVID-19 cases and mortality were low during 2020–2021, severe disease was more frequently observed among males, older adults, employees of NGOs, prisoners, cases with comorbidities, and residents of the northern region. No significant association was observed between vaccination dose and severe COVID-19 in the multivariable regression analysis; overall, severe cases were rare across all vaccination categories. As this was an observational study, the findings should be interpreted as associations rather than causal relationships. The findings highlight the value of nationwide, integrated surveillance systems that link demographic, geographic, clinical severity, and vaccination data to identify populations at higher risk of severe COVID-19. Such systems can support timely risk stratification and inform targeted public health planning. Maintaining a robust surveillance infrastructure alongside evidence-based vaccination programs may strengthen preparedness for future public health emergencies in Lao PDR.